GCMI client Clearside Bio enrolls its first patient in Ph3 macular edema trial
Mass Device sister publication Drug Delivery Business News reported recently that Clearside Bio, a GCMI client, “has enrolled the first patient in a Phase III trial evaluating its eye drug combined with an intravitreally-administered anti-VEGF agent as a treatment for macular edema associated with retinal vein occlusion.” Reporter Sarah Faulkner goes on to write, “The…